ArticleCureus2025
Molecular Characteristics of High-Grade Glioma in Relation to 5-Aminolevulinic Acid (5-ALA) Fluorescence Intensity.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction5-aminolevulinic acid (5-ALA) fluorescence used in glioma surgery has different intensities within tumors and among different patients, some molecular and external factors have been implicated, but there is no clear evidence analyzing the difference of fluorescence according to glioma molecular characteristics. This study aimed to compare molecular factors of glioma samples with fluorescence intensity to identify potential cofounders and associations with clinically relevant tumor features.
methodsTumor samples of high-grade glioma patients operated using 5-ALA for guided resection were included for comparative analysis of fluorescence intensity and molecular features. All the samples were processed under the same conditions. The power for fluorescent stimulation and acquisition time was the same between samples. An inverted fluorescence microscope compared the mean fluorescence for each molecular variation. p53, ATRX and Ki67 expression and IDH1 mutation were assessed by immunohistochemistry. Follow-up of the patients for progression-free survival and overall survival was made.
resultsWe found that the fluorescence intensity for each specific tumor was independent of the methylation of the methylguanine-DNA-methyltransferase (MGMT) promoter region assessed by pyrosequencing, there was no association of fluorescence with p53, ATRX, IDH1 mutation as assessed by immunochemistry. Also, fluorescence intensity has no relation with time of tumor recurrence or overall survival.
conclusionWith the results, we argue that many factors are involved in fluorescence intensity that may be related to the specific metabolic status of the glioma cells analyzed, which is more likely to be responsible for the variation of fluorescence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.